Speakers

Aaron Yarlas

Director, Clinical Outcome Assessments

Ionis Pharmaceuticals

Aimee Jackson

Chief Scientific Officer

Atalanta Therapeutics

Anne Valat

Principal Scientist

Bolden Therapeutics

Apoorva Sarode

Principal Scientist

Genentech Inc

Benjamin Bleier

Associate Professor

Harvard Medical School

Dan Elbaum

Chief Scientific Officer

QurAlis Corp.

Eric Green

Chief Scientific Officer

Maze Therapeutics

Graham Dempsey

Chief Scientific Officer

Q-State Biosciences

Helene Tran

Oligonucleotide Program Lead

Servier

Hideaki Tomita

Group leader (R&D Biology)

Luxna Biotech

Jessica Hurt

Director, Genomic Targets Biology

Biogen Idec

John Lewis

Chief Executive Officer

Entos Pharmaceuticals

Julia Alterman

Assistant Professor

University of Massachusetts Medical School

Mansoor Amiji

University Distinguished Professor

Northwestern University

Marjoke Debets

Director - Research & Development

Eli Lilly & Co.

Mark DeAndrade

Associate Director, CNS Gene Therapy

Korro Bio

Meena Meena

Senior Vice President

Stoke Therapeutics Inc.

Michael Breen

Assistant Professor

Icahn School of Medicine at Mount Sinai

Miguel Rodriguez de los Santos

Postdoctoral Fellow, Icahn School of Medicine

Icahn School of Medicine at Mount Sinai

Nicole Datson

Chief Development Officer

Vico Therapeutics BV

Nikolaos Giagtzoglou

Associate Director CNS Discovery

CAMP4 Therapeutics

Paul Peng

Director

Biogen

Steven Petrou

Chief Scientific Officer

PRAXIS

Sudhir Agrawal

President

ARNAY Sciences

Thomas Gaj

Assistant Professor

University of Illinois

Wen-Hsuan Chang

Head of Target Validation

AcuraStem

William Drury

Director Chemistry Innovation

Deep Genomics

Xiaobo Zhong

Professor

University of Connecticut

Zhen LI

Chief Executive Officer

ADARx Pharmaceuticals Inc.